1. Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients
   Yubo Wang et al, 2021, International Journal of General Medicine CrossRef
2. İleri Evre Küçük Hücreli Dışı Akciğer Kanserlerinde Karsinoembriyonik Antijen Düzeyinin Tedavi Yanıtı ile İlişkisi
   Berna KÖMÜRCÜOĞLU et al, 2024, İzmir Tıp Fakültesi Dergisi CrossRef
3. A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer
   Maoqing Jiang et al, 2022, Frontiers in Oncology CrossRef
4. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs
   Liping Yang et al, 2022, Frontiers in Oncology CrossRef
5. Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients
   Bo-Guen Kim et al, 2022, Journal of Clinical Medicine CrossRef
6. Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis
   Bulin Du et al, 2021, BMJ Open CrossRef
7. New research progress on 18F-FDG PET/CT radiomics for EGFR mutation prediction in lung adenocarcinoma: a review
   Xinyu Ge et al, 2023, Frontiers in Oncology CrossRef